Mora, JCastañeda, APerez-Jaume, SLopez-Pousa, AMaradiegue, EValverde, CMartin-Broto, JGarcia Del Muro, XCruz, OCruz, JMartinez-Trufero, JMaurel, JVaz, M Ade Alava, Ede Torres, C2023-01-252023-01-252017-08-08Mora J, Castañeda A, Perez-Jaume S, Lopez-Pousa A, Maradiegue E, Valverde C, et al. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). Br J Cancer. 2017 Sep 5;117(6):767-774.http://hdl.handle.net/10668/11488First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. This was a prospective, multicentric, non-randomised, open study for patients ⩽40 years with newly diagnosed ES. HR patients (metastatic, axial-pelvic primaries or bone marrow micrometastasis) received 2 window cycles of G/D. Patients with an objective response (OR) to G/D received 12 monthly cycles of G/D after completion of mP6. The primary end point was the OR rate to the G/D window phase and the event-free survival (EFS) and overall survival (OS) for all patients. The study is registered at ClinicalTrials.gov (identifier: NCT00006734). Forty-three patients were enroled, median age 17 years (range, 3-40). After a median follow-up of 43.4 months, the 5-year OS rate is 55.0% (95% CI, 41-74%) with an EFS of 50.0% (95% CI, 36-68%). The 5-year OS and EFS rates for standard risk (SR) patients was 76.0% (95% CI, 57-100%) and 71.0% (CI, 54-94%); for HR 36.0% (CI, 20-65%) and 29.0% (CI, 15-56%). Twelve of 17 (70.6%) high-risk (HR) patients showed an OR (7 PR and 5 SD) to G/D window therapy. The 5-year OS rate for patients ⩽18 years of age was 74.0% (CI, 56-97%) and 31.0% for >18 years (95% CI, 15-66%), P18 years (95% CI, 15-66%), P Age at diagnosis is an independent prognostic factor superior to the presence of metastases with 18 years as the strongest cut-off. The mP6 regimen provided survival curves that plateau at 3 years and G/D produced significant responses in HR-ES that is worth further exploring.enAttribution-NonCommercial-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-sa/4.0/gemcitabinedocetaxelEwing sarcomaadolescent and young adult sarcomasminimal residual disease managementAdolescentAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsChildChild, PreschoolDeoxycytidineDisease-Free SurvivalDocetaxelHumansKaplan-Meier EstimateOdds RatioPrognosisProspective StudiesSarcoma, EwingSpainSurvival RateTaxoidsGemcitabineresearch article28787430open accessMetástasis de la NeoplasiaMetástasis de la NeoplasiaSarcoma de EwingSupervivencia sin ProgresiónMicrometástasis de NeoplasiaMédula ÓseaDocetaxelGemcitabina10.1038/bjc.2017.2521532-1827PMC5589997https://www.nature.com/articles/bjc2017252.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589997/pdf